Last checked at 13 Jul 2020 11:45
Renalytix AI plc
("RenalytixAI", the "Company")
Result of General Meeting
Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that all resolutions proposed at the General Meeting held earlier today were duly passed.
The resolutions were duly approved by shareholders on a poll. The results of the poll are as follows:
Resolution | Votes For | % of Shares Voted | Votes Against | % of Shares Voted | % of ISC voted | Votes Withheld |
1. Allotment of shares (ordinary resolution) | 38,486,100 | 99.96 | 15,728 | 0.04 | 64.80 | 814 |
2. Approval of the 2020 ESPP (ordinary resolution) | 38,500,260 | 99.99 | 2,382 | 0.01 | 64.80 | 0 |
3. Approval of the 2020 EIP (ordinary resolution) | 32,363,912 | 84.06 | 6,137,916 | 15.94 | 64.80 | 814 |
4. Disapplication of pre-emption rights (special resolution) | 38,483,901 | 99.95 | 17,927 | 0.05 | 64.80 | 814 |
Votes withheld are not votes in law and have not been counted in the calculation of the proportion of vote "for" or "against" a resolution.
Defined terms in this release have the same meaning as in the circular sent by the Company to its shareholders on 25 June 2020.
For further information, please contact:
Renalytix AI plc | www.renalytixai.com |
James McCullough, CEO | Via Walbrook PR |
|
|
Stifel (Nominated Adviser) | Tel: 020 7710 7600 |
Alex Price / Nicholas Moore |
|
|
|
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com |
Paul McManus / Lianne Cawthorne | Mob: 07980 541 893 / 07584 391 303 |